Mr Colin Hayburn United Kingdom

Almac provides a comprehensive range of integrated services from research through to commercialisation.  Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.   

Services Offered
Almac’s integrated solutions extend from research to commercialisation and include:

Biomarker Discovery & Development:
·         Companion Diagnostic Development
·         Genomic Services
·         Bioinformatics Consultancy
·         Proprietary Discovery Arrays

API Services & Chemical Development:
·         API Development & Manufacture
·         Peptide & Protein Technology
·         Accelerated First in Man Solution
·         Solid State Services
·         Isotope Chemistry
·         Biocatalysis
     
Pharmaceutical Development:
·         Preformulation & Early Stage Development
·         Scale Up and Late Stage Development
·         Clinical Trial Manufacture
·         Contained Development & Manufacture

Analytical Services:
·         Physical & Chemical Characterisation
·         Method Development & Validation
·         API & Drug Product Testing
·         Stability Testing

Clinical Trial Supply:
·         Comparator Blinding
·         Packaging & Labelling
·         QP Release
·         Global Distribution & Supply Chain Management

Clinical Technologies:
·         IVR / Web
·         ePRO
·         Statistical Services

Commercial Services
·         Manufacturing & Packaging
·         Product Launch & Distribution

Come and see us at booth #70

Company Type
Almac Group

Dr Guy Hill

Arecor enables biologics to be more stable; highly-concentrated; and durable to temperature. Arecor has a proprietary and patented technology platform for improving the stability of a range of therapeutic proteins including vaccines.

Company Type
Arecor
LinkedIn logo

Dr Catherine Hunter

CrystecPharma applies the latest supercritical fluid technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies. Crystec supercritical fluid technologies can be applied to both small drug molecules and biotechnologically sourced drugs.

Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.

Come and see us at booth #73

Company Type
CrystecPharma
LinkedIn logo